Finally, the potential role of p53 and BRCA1/2 as biomarkers for IGF1R-directed therapies in endometrial cancer (and most likely other types of cancer) must be confirmed by larger cell-based and patient analyses. This evidence concerns the gene IGF1R and endometrial cancer.